Our approach is anticipated to work in patients with weakened immune systems and facilitate a therapeutic response. We have built a portfolio of immunotherapies which are designed to target a range of tumor types including certain lung, gastric and esophageal cancers. We are also working to develop immunotherapies using our unique approach to target Head & Neck cancers, Lung squamous cell carcinoma and cervical cancer. We believe that targeting tumor cells via recognition of unique HLA-peptide complexes on tumor cells with multi-specific antibodies presents a meaningful opportunity to expand the benefits of immunotherapy to more patients.
Gritstone is excited to announce that we have partnered with MBC Biolabs, one of the Bay Area’s leading biotech incubators, at their San Carlos location.
With 8-10 applicants for every space that opens and over $20 billion in raised capital, MBC Biolabs has become the most exclusive life science incubator in the Bay Area, offering state-of-the-art facilities, instrumentation, and equipment as well as operational support.
Gritstone has assembled a group of distinguished scientific founders and advisers, a highly experienced leadership team, and a seasoned board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy.
CEO
A seasoned financial professional with a distinguished career in the multinational corporate sector. Previously served as the Senior Vice President of Tax at Cardinal Health. He has also worked a Partner at Pricewaterhouse Coopers and as Director of Tax at Gencorp.
VP of Operations
Previously Director of Marketing Communications at Permission.io, a fintech startup. Rachel also served on TikTok's legal team in the Trust & Safety department. She has significant experience in technology law, management, and business administration.
Gritstone Bio engages a select group of executive-level and industry-leading consultants to provide strategic guidance across key areas of the company. These experts play a critical role in advising on scientific direction, supporting operational decisions, and informing high-level business strategy. Their deep expertise ensures that Gritstone remains at the forefront of innovation while maintaining a disciplined and informed approach to growth and development.
At Gritstone, we are committed to progressing the field of oncological immunotherapy. We aim to combine novel science with a focus on culture and teamwork, and are looking for passionate, innovative people to join us.
read more